TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01650129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 50
Description: Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
Study: NCT04355728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.
Description: UC-MSC will be administered at 100x10\^6 cells/infusion administered intravenously in addition to the standard of care treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle + Heparin along with best supportive care
Description: Best supportive care treatment per the treating hospital protocol.
Study: NCT03829800

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure® Abbott Nutrition
Description: Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucerna® Abbott Nutrition
Description: Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diasip® Nutricia Advanced
Description: Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glicolab®
Description: Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
Study: NCT01335308

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Practitioners will receive 2 hour obesity lecture and ½ day protocol training. Families recruited are given parent education materials. Outcomes will be collected at 1 year and 2 years after enrollment
Study: NCT03273972

Intervention type: OTHER
Group type: OTHER
Intervention: AE/SAE review & reporting
Description: Monitor safety from the point of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dosing
Description: To be performed at the end of the visit following completion all other study visits

Intervention type: DRUG
Group type: OTHER
Intervention: Dosing
Description: To be performed at the end of the visit following completion all other study visits
Study: NCT02326883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Management
Description: The Care Management intervention includes routine outreach to assess ongoing risk of suicide attempt and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
Study: NCT04626063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Patients were treated with etodolac 400mg twice a day plus magnesium oral supplementation once a day for acute low back pain and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Patients were treated with etodolac 400mg twice a day for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Patients were treated with etodolac 400mg twice a day plus 500mg paracetamol twice a day paracetamol for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
Study: NCT01335308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Dose Motivational Interviewing
Description: Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner. Outcomes will be collected at 1 year and 2 years after enrollment
Study: NCT00825370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV opioid
Description: Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
Study: NCT02487875

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Study: NCT02226965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNT2258
Study: NCT05150132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral-B Genius® 8000 power toothbrush with CrossAction brush head with smartphone app(Procter&Gamble,Ohio, USA)
Description: All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone was activated in the PTB with the app group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral-B Genius® 8000 power toothbrush with CrossAction brush head without smartphone app(Procter&Gamble,Ohio, USA)
Description: All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone were not activated in the PTB without the app group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral B ClinicLine Pro-FlexSoft (Procter&Gamble,Ohio, USA)
Description: All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. They were instructed to brush with the Modified Bass technique.
Study: NCT00794586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTI, AZLI
Description: Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTI, AZLI
Description: Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, AZLI
Description: Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, AZLI
Description: Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
Study: NCT03354845

Intervention type: OTHER
Group type: OTHER
Intervention: Deprescribing intervention
Description: Pharmacists assessed the appropriateness of target symptomatic medications and potential for discontinuation. After discussion with pharmacists and consideration of patients' and caregivers' preferences regarding discontinuation or dose reduction, doctors would deprescribe these symptomatic medications. Symptom recurrence, adverse drug withdrawal events (ADWEs), and the need for drug re-initiation or initiation of new symptomatic control medications after deprescribing were monitored and documented in the 1st, 2nd and 6th weeks.
Study: NCT00666562

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Defined Green Tea Catechin Extract
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Defined Green Tea Catechin Extract
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01335308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher Dose Motivational Interviewing
Description: Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner and 6 x visits (in phone or in person) with a Registered Dietitian, also trained in Motivational Interviewing. Outcomes will be collected at 1 year and 2 years after enrollment
Study: NCT00666562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00355797

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rate Adaptive (R) Technology
Description: Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the standard are adaptive pacing mode (DDDR or VVIR) for the long-term follow-up portion of this study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-rate adaptive (DDD) pacing
Description: Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the non-rate adaptive pacing mode (DDD or VVI) for the long-term follow-up portion of this study.
Study: NCT04279353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Description: this intervention is a 4 weeks program with logbook and follow up during intervention
Study: NCT01526330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14618
Description: A mg/disc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14618
Description: B mg/disc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14618
Description: C mg/disc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg/disc
Study: NCT02294604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ethyl alcochol, chlorhexidine and moisturizers

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: povidone-iodine
Study: NCT05213156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxatrex
Description: 0.3% ofloxacin eye drops in single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxatrex
Description: 0.3% ofloxacin eye drops in single doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxatrex
Description: 0.3% ofloxacin eye drops in single doses
Study: NCT02368639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel Healthcare PAP Device
Description: The device is a modified version of the Fisher \& Paykel Icon continuous positive airway pressure (CPAP) device, which is a fully released product in New Zealand.
Study: NCT05334173

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB) measuring the lengh of the common limb
Description: The patients are randomized to Type 1 laparoscopic RYGB (150cm alimentary limb and 70cm biliopancreatic limb) or type 2 laparoscopic RYGB (70cm alimentary limb and 150cm biliopancreatic limb). In both groups, the total intestinal length is measured to determine the size of the common limb. We introduce a 10 cm ruler into the abdominal cavity to measure the bowel and then extract it. LRYGB is made with linear stapler anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB) measuring the lengh of the common limb
Description: The patients are randomized to Type 1 laparoscopic RYGB (150cm alimentary limb and 70cm biliopancreatic limb) or type 2 laparoscopic RYGB (70cm alimentary limb and 150cm biliopancreatic limb). In both groups, the total intestinal length is measured to determine the size of the common limb. We introduce a 10 cm ruler into the abdominal cavity to measure the bowel and then extract it. LRYGB is made with linear stapler anastomosis.
Study: NCT01841554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioband
Study: NCT02110394

Intervention type: OTHER
Intervention: bendamustine
Description: Routine practice

Intervention type: OTHER
Intervention: rituximab
Description: Routine practice
Study: NCT03644888

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycle ergometer training
Description: Already in arm/group descriptions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer training
Description: Already in arm/group descriptions

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cycle ergometer training
Description: Already in arm/group descriptions
Study: NCT00666562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study: NCT03947411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Phosphate
Description: Take the dosage of Oseltamivir Phosphate recommended according to the instructions.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiyanping injection+Oseltamivir Phosphate
Description: Take the dosage of Oseltamivir Phosphate recommended according to the instructions.Xiyanping injection intravenous administration of 0.4mL/kg/day ,QD for 7-10 days.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
Study: NCT00666562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT02326883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training
Description: The Skills Training intervention uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Those assigned to usual care will not be contacted at all by study staff and will continue to receive usual care from treating primary care and mental health providers.
Study: NCT03442062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment Feedback Incentives and eXchange
Description: The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
Study: NCT03455790

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aerobic Capacity
Description: Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests.
Study: NCT03442062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment Feedback Incentives and eXchange
Description: The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician-to-physician engagement
Description: Physician-to-physician engagement is a quality improvement strategy in which trained physician educators deliver a 60 minute consultation via interactive webinar. The consultations will be delivered to providers in primary care clinics and will include didactic instruction on HPV-related cancers, HPV vaccination, communication training, and assessment and feedback about each clinics' vaccination coverage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician-to-physician engagement
Description: Physician-to-physician engagement is a quality improvement strategy in which trained physician educators deliver a 60 minute consultation via interactive webinar. The consultations will be delivered to providers in primary care clinics and will include didactic instruction on HPV-related cancers, HPV vaccination, communication training, and assessment and feedback about each clinics' vaccination coverage.

Intervention type: OTHER
Group type: OTHER
Intervention: Active Intervention Control
Description: Active Intervention Control will be a remotely delivered quality improvement strategy on a clinical topic other than HPV vaccination.
Study: NCT01820832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol 0.5 ug/BIW for 24 weeks.
Study: NCT02467244

Intervention type: DRUG
Intervention: Levothyroxine
Description: At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
Study: NCT02107898

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT04969055

Intervention type: OTHER
Intervention: Not
Description: Not
Study: NCT03455790

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Aerobic Capacity
Description: Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests.
Study: NCT02107898

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT02552602

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin A
Description: Multivitamin containing 7 micronutrients at recommended daily allowance (RDA)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin B
Description: Multivitamin containing 22 micronutrients at RDA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin C
Description: Multivitamin containing 22 micronutrients at three times the RDA
Study: NCT03515187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% sodium hyaluronate ophthalmic solution
Description: one to two drops in eye, four times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% sodium hyaluronate ophthalmic solution
Description: one to two drops in eye, four times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% sodium hyaluronate ophthalmic solution
Description: one to two drops in eye, four times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% sodium bromide solution
Description: one to two drops in eye, twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% sodium bromide solution
Description: one to two drops in eye, twice per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meibomian gland massage
Description: Physiotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle